Published in Am J Cardiol on August 01, 1981
Community study of the causes of "natural" sudden death. BMJ (1988) 2.44
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart (2002) 1.66
Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging (2007) 1.48
Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child (1984) 1.29
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J (1989) 1.10
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart (2004) 0.98
Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. Br Heart J (1995) 0.93
Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr (2013) 0.89
Cardiac arrhythmias in hypertrophic cardiomyopathy. Br Heart J (1982) 0.87
Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J (1994) 0.85
Molecular basis of hypertrophic and dilated cardiomyopathy. Tex Heart Inst J (1994) 0.83
Hypertrophic cardiomyopathy presenting with 3rd-degree atrioventricular block. Tex Heart Inst J (1997) 0.80
Autonomic function in hypertrophic cardiomyopathy. Br Heart J (1993) 0.80
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ (2012) 0.80
Hypertrophic cardiomyopathy in identical twins. Br Heart J (1989) 0.79
Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy. Postgrad Med J (1986) 0.76
Sudden death in young people due to hypertrophic cardiomyopathy. Arch Emerg Med (1989) 0.75
Potential mechanisms of improvement after various treatments for hypertrophic obstructive cardiomyopathy. Tex Heart Inst J (1995) 0.75
Ventricular premature beats--story petrels? Br Med J (Clin Res Ed) (1982) 0.75
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 0.75
Approaches to prevention and early detection of cardiomyopathies: memorandum from a WHO meeting. Bull World Health Organ (1986) 0.75
Problems in diagnosis and management of hypertrophic cardiomyopathy. Postgrad Med J (1991) 0.75
Does treatment influence the natural history of patients with hypertrophic cardiomyopathy? Drugs (1985) 0.75
[Long term electrocardiography (Holter monitoring)]. Herzschrittmacherther Elektrophysiol (2008) 0.75
Can we predict sudden cardiac death? Drugs (1991) 0.75
The value of oral amiodarone in the treatment of ventricular arrhythmias in heart disease. Drugs (1991) 0.75
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med (1982) 8.62
Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol (2000) 7.39
Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 6.49
Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 6.43
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med (1991) 6.08
Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science (1998) 5.98
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1994) 4.94
An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) N Engl J Med (1998) 4.92
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med (2000) 3.99
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med (1991) 3.80
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Profile of preparticipation cardiovascular screening for high school athletes. JAMA (1998) 3.36
Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation (1973) 3.31
Colitis cystica profunda. Am J Clin Pathol (1966) 3.28
The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med (1991) 3.17
Sudden death in young athletes. Circulation (1980) 3.05
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med (1977) 2.94
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med (1987) 2.88
Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation (1979) 2.68
Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol (1995) 2.62
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol (2000) 2.61
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol (1987) 2.60
Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation (1989) 2.56
"Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol (1988) 2.53
A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med (1989) 2.45
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol (1981) 2.37
Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol (2000) 2.33
Causes of sudden death in competitive athletes. J Am Coll Cardiol (1986) 2.31
Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med (1988) 2.30
Comparative left ventricular dimensions in trained athletes. Ann Intern Med (1975) 2.27
Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol (2001) 2.22
Prognosis of surgically corrected coarctation of the aorta. A 20-year postoperative appraisal. Circulation (1973) 2.21
Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol (1986) 2.18
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med (1987) 2.18
Preparticipation cardiovascular screening for US collegiate student-athletes. JAMA (2000) 2.10
Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation (1976) 2.08
Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol (2000) 2.05
Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med (1999) 2.05
Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation (2000) 2.03
Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation (1981) 2.00
Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med (1986) 2.00
Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation (2001) 2.00
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation (1994) 1.98
Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med (1973) 1.96
Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation (1975) 1.96
Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med (1989) 1.95
Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris. Circulation (1971) 1.89
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation (1982) 1.87
Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings. Circulation (1974) 1.85
Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med (1966) 1.83
Angina caused by reduced vasodilator reserve of the small coronary arteries. J Am Coll Cardiol (1983) 1.82
Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation (1985) 1.81
Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation (1979) 1.80
Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol (1978) 1.78
"Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol (1978) 1.76
Mitral valve prolapse in the general population. 1. Epidemiologic features: the Framingham Study. Am Heart J (1983) 1.72
Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol (1986) 1.70
Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol (1984) 1.67
Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation (1981) 1.66
The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis (2000) 1.66
Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.65
Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation (1982) 1.64
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol (1979) 1.63
Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J (1983) 1.61
Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med (1967) 1.61
Limitations of the electrocardiographic response to exercise in predicting coronary-artery disease. N Engl J Med (1975) 1.61
Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation (2001) 1.61
Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. J Am Coll Cardiol (1986) 1.59
Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. Am J Pathol (1975) 1.59
A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res (1998) 1.59
Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol (1987) 1.57
Asymetric septal hypertrophy in childhood. Circulation (1976) 1.56